Clinical Trials | December 09, 2025
Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
The study met its primary endpoint and all 11 secondary efficacy endpoints
The study met its primary endpoint and all 11 secondary efficacy endpoints
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Subscribe To Our Newsletter & Stay Updated
